Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Teresa Kerge

Interventional Pain Medicine Fredericksburg, VA Medical Doctor

NPI 1851617120 CMS profile 84466

2549 Cowan Blvd, Fredericksburg, VA 22401

Open in the dashboard

General payments

$1,614

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Teresa Kerge of Fredericksburg, VA is reported in the CMS Open Payments database as having received $1,614 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 32nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $302 4
2024 General $123 2
2023 General $37 2
2022 General $107 7
2021 General $257 17
2020 General $333 21
2019 General $455 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Teresa Kerge
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Teresa Kerge were reported at $302. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Teresa Kerge Interventional Pain Medicine median Middle half National median
2019 $455 $684 $216–$2,079 $163
2020 $333 $382 $122–$1,109 $114
2021 $257 $552 $167–$1,554 $132
2022 $107 $605 $187–$1,924 $149
2023 $37 $671 $195–$1,915 $160
2024 $123 $684 $206–$1,837 $164
2025 $302 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $282 3 payments
  2. Scilex Pharmaceuticals Inc. $272 17 payments
  3. Collegium Pharmaceutical, Inc. $217 13 payments
  4. Medtronic, Inc. $122 8 payments
  5. Curonix LLC $102 1 payment
  6. Medtronic USA, Inc. $95 6 payments
  7. Zyla Life Sciences $79 6 payments
  8. Pfizer Inc. $70 5 payments
  9. Abbott Laboratories $65 4 payments
  10. Horizon Therapeutics plc $56 4 payments
  11. Other $254 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,614 83 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $282 3 payments
  2. XTAMPZA $172 10 payments
  3. ZTLido $138 8 payments
  4. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $134 9 payments
  5. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $102 1 payment
  6. VECTRIS $81 5 payments
  7. SPRIX $79 6 payments
  8. EMBEDA $55 4 payments
  9. LYRICA $55 4 payments
  10. RELISTOR $50 3 payments
  11. Other $654 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

153

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$2,359

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

32.7%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 13 $796
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 50 $711
Gabapentin Generic 27 $389
Celecoxib Generic 12 $219
Cyclobenzaprine Hcl Generic 17 $138
Methocarbamol Generic 12 $94
Diazepam Generic 22 $13

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$169,846

Of which drugs: $1,412

Medicare patients

534

Average age 74

Services billed

5,191

332 women, 202 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 34%
Diabetes 33%
Chronic kidney disease 25%
Depression 22%
Atrial fibrillation 18%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 187 1,644 $1,242
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 155 1,899 $170

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record